ABSTRACT
Epigenetic control provides a mechanism for the reversible silencing of telomerase expression that occurs as a natural consequence of differentiation. Significant overlap between indirect telomerase regulation pathways and cell cycle checkpoint pathways exist, suggesting that these discrete genetic elements (namely, p21, p53, and hTERT) synergistically cooperate to inhibit tumorigenesis. Mutations in these pathways have been known to contribute to cancer formation. However, the incorporation of epigenetic regulatory mechanisms provides another line of defense against these negative occurrences. These proteins are also implicated in the process of senescence, caused in eukaryotic cell lines by telomere shortening. Although the debate continues, there is significant evidence to classify the process of cellular senescence as an in vitro model for human aging. In addition, the study of stem cells gives information about the down-regulation of hTERT in the aging process. Diseases such as Werner's syndrome, ATM (ataxia telangiectasia mutated kinase), DKC (dyskeratosis congenita), and atherosclerosis have been linked to aberrant telomerase expression and other aging-related tissue malfunctions could be related to the presence of senescent cells changing the cellular microenvironment. Therefore, restoring telomerase activity as a putative therapeutic strategy necessitates further study to elucidate the intricacies linking genetic and epigenetic modulations of hTERT.
TELOMERASE AND TELOMERES
Telomerase is a DNA polymerase that uses an RNA template in a reverse transcription reaction to synthesize DNA termini during the replication process. The nascent DNA synthesized by telomerase is referred to as telomeres, and is essential to counteract the "endreplication problem" in linear chromosomes. Telomeres also serve to preserve the chromosomal integrity by preventing rearrangements, nuclease degradation, and endto-end chromosomal fusions (1) (2) . The telomerase holoenzyme is a ribonucleoprotein complex and is composed primarily of two subunits. In humans, the catalytic subunit of telomerase is hTERT (human telomerase reverse transcriptase), which confers its reverse transcription activity; and the RNA component, hTR, that is complementary to the 6-nt telomeric repeat sequence, serves as a template for elongation of the telomeres (3) (4) (5) .
The hTR component of telomerase is ubiquitously expressed in most cell types including telomerase-negative cells such as differentiated somatic cells (6) (7) . hTERT, on the other hand, is tightly regulated during differentiation and is almost undetectable in most somatic cells (8) . A positive correlation has been found between the amount of hTERT mRNA and the activity of telomerase, suggesting that telomerase is regulated at the gene transcriptional level of hTERT (9-12).
Telomere attrition rate
Telomerase is expressed at different levels in various cell types, mostly according to the proliferative ability of the cells. It is highly expressed in stem cells, germ cells, other self-renewing tissues such as keratinocytes (basal epidermal cells), and hematopoetic cells (13) (14) . As discussed above, hTERT expression is positively correlated with telomerase activity, and thus inhibition of hTERT usually results in telomeric attrition. Telomerase activity is usually repressed in somatic cells, but is reactivated in immortalized cell lines and human cancers (15) . Due to this repression of telomerase, normal somatic cells experience telomeric attrition at a mean loss of 30-150 bps of telomeric DNA per replication (16) , until a critical minimum telomeric length is reached whereby the cells then experience cellular senescence (17) . Consistent with the Hayflick Limit theory, which states that cells have a maximum number of population doublings before undergoing senescence, scientists now propose that telomeres serve as a biological clock of the aging process.
In contrast, it is interesting to note that exogenous expression of hTERT can immortalize cells (18) and similarly restore biological function in senescent cell populations (19). About 70% of immortalized human somatic cell lines (20) and 90 -95% of human cancer cells express high levels of telomerase, comparable to cells normally expressing telomerase such as germline cells. This shows a strong correlation between telomerase expression, telomere length maintenance and tumorigenesis or immortalization (21-22). Thus, in the normal phenotype, it is important for the cell to be able to strike a balance between telomere maintenance and the rate of telomere attrition. This article discusses the epigenetic regulation of telomerase, factors or mechanisms that may modulate its function in the cell, and the effect on telomeres.
hTERT epigenetic control 2.2.1. DNA methylation of hTERT promoter
Recent evidence suggests that gene expression can be altered markedly via several diverse epigenetic mechanisms that can lead to permanent or reversible changes in cellular behavior. DNA cytosine methylation is the most prevalent eukaryotic DNA modification and constitutes one of the best understood epigenetic phenomena. There is substantial evidence that DNA methylation plays a critical role in gene regulation during development and cellular differentiation. Currently, there are three families of DNA methyltransferases (DNMTs) identified to be involved in the in vivo methylation pathways in both mouse and human models. The DNMT1 family is involved in maintenance methylation because they show a preference towards methylating hemimethylated DNA substrates in vitro (23). DNMT1 has also been shown to display some de novo methylating activity (24), as is the case with DNMT3a and DNMT3b. The DNMT3 family is considered to be largely responsible for establishing new methylation patterns (25).
There has been much debate about the methylation status and resulting transcriptional activity of the hTERT promoter. Gene promoters that are rich in CpG dinucleotides are highly susceptible to DNA methylation at the cytosine residues. In general, CpG island methylation correlates inversely with gene expression, because it may prevent the binding of methylation-sensitive transcription factors. Retinoic acid induced differentiation of human leukemia (HL60) cells and human teratoma cells resulted in a decreased expression of hTERT, and a corresponding increase in hTERT promoter methylation. Interestingly, the methylating patterns at the promoter also changed through the differentiation process (153) . In contrast, the promoter of hTERT has been found to be hypermethylated in tumor tissue and cell lines that were telomerase positive, as compared to telomerase negative normal tissues where hypomethylation was observed (26). Treatment with the demethylating reagent 5-aza-2'-deoxycytidine caused reactivation of the hTERT promoter in differentiated HT cells (153) , while a similar treatment inhibited its expression in human prostate cancer cells (27).
It is evident that hTERT expression is multi-fold and methylation studies of the promoter is cell-type specific possibly based on the expression of activators and repressors, and the relevant chromatin structure. It is plausible that epigenetic changes in the chromatin provides access to these transcriptional factors, and a change in the methylation pattern of the promoter suggests a mechanism in which access to methylation-sensitive transcription factors is regulated. It is also probable that it is the differential binding of these factors that eventually results in the heterogenous expression of hTERT as a result of these epigenetic changes.
Histone modifications by acetylation/methylation
Many genes are not modulated solely by transcriptional factors, but also by accessibility of the transcriptional factors to the promoters. Protein access to DNA is modulated by chromatin structure. As the dynamic chromatin switches between euchromatin and heterochromatin, accessibility increases and decreases respectively. Mainly, chromain structure can be changed by histone modifications such as acetylation and methylation Figure 1 . p21, cdk2, cyclin E, pRB, and E2F interaction and the resulting effects on the cell cycle. In proliferating cells, phosphorylation of pRB by cdk2-cyclin E complex prevents binding of pRB to E2F, thus enabling E2F to be involved in the transcription of S-phase related proteins. In differentiated or senescent cells, p21 can act as a CDKI to prevent the downstream phosphorylation of pRB, allowing pRB to sequester E2F, and eventually preventing the entry of the cell into S-phase.
of appropriate amino acid residues. Histone proteins carry basic charges and are wrapped around by negatively charged DNA molecules. The electrostatic attraction helps to sustain a stable association between these two molecules. Acetylation of the histone proteins can neutralize the charge on the histones, and therefore attenuates the attraction force between DNA and histone proteins, leading to an opened chromatin structure. Conversely, deacetylation of histones causes histone tails to tightly associate with DNA, which forms a repressive chromatin structure that is less accessible to transcription factors. Such reversible modifications of the histone proteins can effectively alter the conformation of a given region of chromosomal DNA.
In addition to the acetylation modification, other post-translational modifications of the histone proteins including methylation have also been described to affect transcriptional regulation and gene expression (28). For example, human repetitive elements such as Alu elements contain a high level of H3-Lys9 methylation, which is proposed to play a role in the suppression of recombination among these elements (29). Methylation modification of the histone lysine residues may exist in three different forms: mono-, di-and tri-methylation. G9a histone methyltransferase (HMTase) is indicated to be responsible for all detectable dimethylation and a significant amount of monomethylation within the silent euchromatin, whereas Suv39h1 and Suv39h2 HMTases may direct trimethylation specifically at heterochromatin regions (30). Telomeres are normally enriched in trimethylated H3-Lys9 (31).
Both DNA methylation and histone acetylation have been extensively studied and recognized as global epigenetic mechanisms regulating gene transcription. Observations from the past have revealed a strong link between these two processes. At the hTERT promoter, for example, they are found to cooperate with each other at the chromatin level to influence the regulation of hTERT expression (32). The different methyl-CpG binding domain proteins such as MeCP2, MBD1, MBD2 and MBD3 may act as mediators between DNA methylation and histone acetylation. They recognize and bind to symmetrically methylated-CpG dinucleotides, recruit histone deacetylase and mediate transcriptional silencing by deacetylating histones in the vicinity of the promoter. The synergistic role between DNA methylation and histone deacetylation events was also documented by studies showing that direct associations between DNMT and HDAC repressor complexes, which are recruited to replication foci through interactions with proliferating cell nuclear antigen (PCNA) (33-36), interact with cell cycle regulator, p21 to regulate hTERT expression (see section 2.3).
Epigenetic modulations of telomerase via indirect pathways 2.3.1. p21
WAF1/Cip1/SDI1 and p53 cell cycle checkpoint Since studies have shown that the stable proliferation or senescence of cells is dependent on telomerase activity and telomeric length, it is important to study the relationship of telomerase and cell cycle control mechanisms. The main cell cycle regulatory machinery includes interplay of protein complexes consisting of cyclins, cyclin-dependent kinases (CDKs) and cyclindependent kinase inhibitors (CDKIs). The phosphorylation of cyclin proteins by their respective CDKs is necessary for the progression of the cell cycle through the G1/S checkpoint into S-phase. p21 WAF1/Cip1/SDI1 (p21), a CDKI, forms a complex with cyclin E and CDK2 to prevent the downstream phosphorylation of retinoblastoma protein (RB), thereby inhibiting G1/S progression of the cell cycle ( Figure 1 ). p53 is a major player in cell cycle control, and works in conjunction with p21 to apply the brakes at the G1/S checkpoint.
In 1996, Holt et al. demonstrated that telomerase is consistently detectable in immortalized human leukemia (HL60) and cancerous human teratoma (HT1080) cell lines at all stages of the cell cycle (37). This lack of variation in telomerase levels may be explained by the fact that the enzyme has a half-life of about 24 hours (38). In the same study, all-trans-retinoic acid differentiated HL60 cells and telomerase-positive contact-inhibited quiescent Swiss fibroblast cell-line NIH3T3 cells displayed minimal telomerase activity, suggesting a mechanism for the downregulation of the enzyme activity during G 0 phase. Passaging of the contact-inhibited NIH3T3 cells allows the exit of G 0 into G 1 phase, leading to the reactivation of telomerase. This indicates that the inactivation of the enzyme is a reversible process and that telomerase activity does not correlate with DNA synthesis (37). In this section, we will explore the role of epigenetics in the transcriptional regulation of telomerase by cell cycle control proteins.
The p53 / p21
WAF1/Cip1/SDI1 linked pathways and hTERT p53 is a tumor suppressor gene that is associated with differentiation, apoptosis, DNA repair and control of cell cycle progression. Mutation of the p53 gene is associated with about 10,000 types of human tumors (39). p53 protein regulates the transcription of many genes, both negatively and positively, thereby influencing the entry processes with which it is associated. The hTERT gene has two p53 binding sites at -1877 and -1240 (+1 denotes the start of transcription) upstream of the 5' promoter region. Overexpression of p53 and binding of the protein at these two sites represses the hTERT promoter with the assistance of transcription factor Sp1 recruitment (40). CDKI p21 has a p53 responsive element at -2281 / -2262 in the distal region of its promoter. Full transactivation of the p21 promoter is enabled by the binding of p53 protein, Sp1 proteins and related factors at the promoter region (41-42). The downstream effect of p53 transactivation of the p21 promoter is the negative regulation of the cell cycle, thereby preventing progression past the G1/S checkpoint (43) . At the same time, p53 expression leads to the repression of the hTERT promoter, thereby effectively shutting down the cell cycle ( Figure 2 ). In mammary epithelial cells, abrogation of p53 function induces cellular immortality, probably through the reactivation of telomerase (40). On the other hand, normal human astrocyte cells (NHAs) senesced upon exogenous p21 expression and could not be induced to reproliferate with hTERT expression, indicating that senescence is directly p53-dependent and that hTERT is a downstream regulating event (44).
Effect of p21
WAF1/Cip1/SDI1 on hTERT p21 WAF1/Cip1/SDI1 (p21) is a CDKI belonging to the CIP/KIP family of negative cell cycle regulators along with p27 Kip1 . The p21 gene is ubiquitously expressed in mammalian cells and is speculated to be the universal inhibitor of CDKs (45-46). As a major player in cell cycle arrest, p21 is critical for the control of differentiation, senescence, and apoptosis. Overexpression of p21 induces a correlative repression of hTERT, which has been demonstrated in human glioma cells (47) and squamous cell carcinoma cell lines, in which telomerase expression is abnormally elevated (48) .The p21 promoter has been shown to be generally CpG rich and to contain a 78 base pair GC-rich region near the TATA box that is required for induction of the gene (42, 49) , indicating possible epigenetic regulation of its expression through changes in DNA methylation. Studies have shown that treatment of human diploid fibroblast HCA2 cells with 5-aza-2-deoxycytidine, a potent DNMT inhibitor, caused a rapid global decrease in methylation followed by an elevation in p21 mRNA and protein levels. The cells were found to be arrested at both G1 and G2 phases of the cell cycle (43) . Moreover, transfection of antisense DNMT1 into human breast cancer MDA231 cells revealed a correlation between the decrease in DNMT1 and an increase in p21 protein levels (50) . DNMT1 is also known to bind to proliferating cell nuclear antigen (PCNA), an auxillary factor for DNA replication and repair. This complex may be formed as a recruitment mechanism to methylate newly replicated DNA (51) . However, upregulation of p21 can cause a competitive inhibitory effect of DNMT1 to the PCNA complex (52), suggesting that p21 may play a role in the epigenetic regulation of DNA methylation (51) . The current opinion is that p21 may affect the expression of hTERT, but the exact mechanism by which it acts is not conclusive. Collective data suggests, however, that the regulation of hTERT by p21 is multi-fold and indirect. An example of this interaction would be via epigenetic mechanisms such as through competition for the PCNA complex. Direct regulation of DNA methylation could affect the methylation status of the hTERT promoter and affect its activity. Other examples of hTERT regulation by p21 include G0/G1 cell cycle arrest mechanisms. Specifically, the effect of p21 down-regulation leads to the activation of This table summarizes the properties of key telomere-associated proteins, such as their binding targets, the downstream functions, and eventual result on telomerase activity RB and results in the release of transcription factor E2F, which transcribes genes pertinent for S-phase ( Figure 1 ). Evidence has shown this to be sufficient to disrupt p53-dependent repression of hTERT, suggesting that p21 plays an important role in mediating p53-dependent hTERT repression (53) . Similarly, the abrogation of E2F1 activity by a dominant negative mutant or inactivation of RB using RNAi and viral oncogenes were also able to abolish p53-dependent hTERT repression (53) . This illustrates the importance of cell cycle control on hTERT activity.
Alternate lengthening of telomeres
Approximately 10% of tumors maintain telomeric lengths via a telomerase-independent pathway referred to as "alternate lengthening of telomeres" (ALT) [54] . More than 80% of ALT cell lines are p53-negative. It is possible that the ALT system utilizes telomeric-DNA recombination. Moreover, p53, which normally suppresses DNA-recombination events, decreases the rate of ALT (56) . Among the characteristics of ALT cells that point toward recombination-based models is the fact that these cells lack telomerase activity and yet are able to maintain their telomeres. However, it should be noted that there are occasional tumors that are able to exist devoid of both telomerase and ALT (57) . Also, ALT cells possess heterogeneous telomere lengths, suggesting that the telomeres are not undergoing the same rate of loss of telomere lengths per chromosome, and that recombination could be a feasible explanation. Other indications of a recombination-based ALT system include the presence of ALT-associated promyelocytic leukemia bodies (APBs). These APBs consist of a co-localization of promyelocytic leukemia protein (PML) nuclear body, recombination proteins (e.g. RAD proteins), telomere binding proteins (TRF1 and TRF2), and telomeric DNA (58) .
Studies have demonstrated that labeling a single telomere in ALT cell lines led to a spread of labeled telomeres, thus supporting the recombination theory, and suggesting that this recombination can occur between telomeres on separate chromosomes (59) . In addition, telomere recombination in a mouse model has also been shown between homologous sister chromatids, and subtelomeric ALT of sister chromatid exchange (SCE) occurs at a particularly high frequency (60) . Quantification of SCE rate in wild-type mice in vitro indicates that regular genomic SCE is superceded by telomeric SCE by 20-fold. This indicates that telomeric DNA is highly susceptible to recombination (54) , and that this type of ALT is a normal occurrence in cells, which is probably due to the tandemly repeated TTAGGG sequence homology. An interesting theory that may explain the natural occurrence of ALT could be that this serves to delay clonal senescence. The transfer of a telomere of a chromosome to another telomere could help prolong the onset of senescence due to the fact that the sister chromatid of the donor chromosome still possesses a long telomere, which will enable the recipient chromosome to continue replicating. The result is that the cell is able to delay senescence (54) .
Another proposed model of recombination-based ALT is the extension of telomeres via DNA polymerase activity. This type of ALT uses the telomere of a chromosome as a DNA template to extend that of a separate chromosome (56) . Since there are genes that have been linked to either increased or decreased rate of ALT such as p53 and scid, it is thus clear that the control of ALT is a multigenic factor (54) . It is also plausible to conclude that whichever the method of ALT, cells must maintain telomeric length above a threshold rate of ALT to sustain proliferation. Therefore a combination of genetic mutations could cause ALT to occur above threshold and result in a transformed phenotype with extended telomeres.
Telomerase recruitment to telomeres -mammalian model
The telomerase recruitment mechanism is an important factor for telomerase mediated telomere extension. Telomere length maintenance is considered homeostatic due to positive and negative feedback mechanisms, as telomere binding proteins serve as positive and negative regulators in this complex network. The complete mechanism of this complex network is still unknown. Proteins involved include: TRF1 (telomere restriction fragment 1), TRF2, hEST1A (human ever shorter telomeres-1A), tankyrases (TRF1 interacting ankyrin-related ADP-ribose polymerase), TIN2 (TRF1 interacting factor 2), PINX1 (Pin2/TRF1 interacting protein), PIP2 (POT1 interacting protein-2), POT1 (protection of telomeres-1) and hRap1 (human repressor activator protein-1) (Table 1, Figure 3 ). Telomerase recruitment to telomeres by other proteins has been studied in depth in both prokaryotes and eukaryotes (S. cerevisiae, S. pombe, D. melanogaster), and in mammals including humans. Although there are intrinsic similarities among these models, they are essentially distinct in nature. Therefore in this section, we will only discuss that of the mammalian model. Both TTAGGG repeat binding factors, TRF1 and TRF2 proteins, bind to duplex telomeric DNA at the TTAGGG repeat array. They are reported to be negative regulators of telomere extension. However, they neither affect the expression of telomerase, nor its enzymatic activity in vitro (61) . Instead, the binding of TRF1 and TRF2 physically prevents telomerase from adding more telomeric repeats by stalling the addition of telomeric repeats by telomerase at telomere replication forks (64) . TRF1 has been demonstrated to be involved in maintaining an equilibrium telomere length in cells, including telomerase-positive human immortal cell lines. Persistent overexpression of TRF1 in human teratoma (HT1080) cells results in a gradual loss of telomere length, while expression of a dominant negative mutant, TRF1, causes the displacement of wildtype TRF1 from telomeres, thus resulting in telomere extension by telomerase (63) . It has been hypothesized that the longer the length of the telomere, the more TRF1 proteins are bound, thus serving as a counting mechanism to regulate telomere extension (reviewed in 64). Another protein, POT1, is hypothesized to work in conjunction with TRF1 in its function of telomere length counting. Although POT1 is able to attach to single-stranded telomeric DNA, abrogation of its DNA binding domain does not diminish its recruitment to telomeres (64) . However, other novel proteins have been identified such as PTOP (65) and PIP2 (66) which are thought to aid in the process of POT1 recruitment to TRF1. de Lange and colleagues have also shown that TRF1 is important for the recruitment of POT1, since removal of TRF1 from telomeres reduced POT1 binding. Furthermore, abrogation of POT1 single-stranded DNA binding domain results in an enhanced elongation of telomeres by telomerase, indicating that POT1 and TRF1 both cooperate to inhibit telomere extension. This also suggests that POT1 functions downstream of TRF1 in the inhibitory response, possibly by transducing the information of telomere length (67) . It is also hypothesized that its inhibitory function could simply be due to physically blocking access of telomerase by binding to the 3'-telomeric overhang (68) .
The overexpression of TRF2 also increases the rate of telomere shortening. This protein serves to protect the 3' chromosomal end by remodeling telomeric DNA into a T-loop (69), thus preventing end-fusions (70) . Furthermore, it has been postulated that the negative regulation of TRF2 is due in part to hRap1, which is yet another negative regulator of telomere extension. It does not bind directly to telomeric DNA, but is recruited by the negative regulator, TRF2. Mutation of the binding sites of hRap1 to TRF2 induces telomere elongation (71).
hEst1A is a single-stranded DNA binding protein, which is able to bind to the hTERT catalytic subunit to recruit the telomerase holoenzyme. This results in the lengthening of telomeres (72) . Overexpression of hEst1A also causes uncapping of chromosomal ends, causing end-to-end fusions (73) Tankyrases (tankyrase 1 and tankyrase 2) are poly (ADP-ribose) polymerases that can donate or accept ADP-ribose and modify their substrates. Tankyrases 1 and 2 possess 85% homogeneity in their amino acid sequence, and display similar enzymatic properties. They may, however, differ in the downstream effects of their poly ADP-ribosylation (74) . It has been demonstrated that these tankyrases can ADP-ribosylate TRF1 to inactivate TRF1 and prevent its attachment to telomeres (75) . The ADPribosylation activity is found to be dependent on the availability of NAD + in vitro. Lower levels of NAD + were associated with reduced modification of TRF1 even at a higher concentration of tankyrase enzyme. Conversely, tankyrase was able to ADP-ribosylate TRF1 in the presence of higher levels of NAD + (75) . These data suggest that the inhibitory effect of TRF1 on telomere extension is regulated by ADP-ribosylation. The regulation of TRF1 attachment to telomeres also determines access of telomerase to telomeres for extension.
TIN2 is a protein that can bind to both TRF1 (77) and tankyrase (78) , and seems to affect tankryase-TRF1 interaction. In fact, TIN2 prevents tankyrase modification of TRF1, such that TRF1 can exert its inhibitory effect on telomere extension, thus controlling the length of telomeres (64) . Further, TIN2 has also been demonstrated to interact with TRF2 to aid in the maintenance of a functionally capped telomere (77) .
PINX, another protein that interacts with TRF1, inhibits the elongation of telomeres by directly interacting with telomerase. It has been described as a potent telomerase inhibitor, and a putative tumor suppressor (78) . However, the exact mechanism in which it interacts with TRF1 and other telomerase binding proteins is still unknown. In vitro, PINX specifically sequesters the hTERT catalytic subunit, inhibiting its function. Overexpression of PINX results in shorter telomeres and decreased telomerase activity. Conversely, deletion of PINX results in longer telomeres and increased telomerase activity in vitro (79) . Furthermore, a loss of PINX in nude mice causes a higher incidence of tumorigenesis (78) , consistent with its role in telomerase inhibition.
CELLULAR SENESCENCE AND AGING

Biological significance
Just as the goal of biomedical research is improving the human condition, the aim of studying human aging focuses on delaying the complex propensities for disease, debilitation, and ultimately death that accompany the aging process. It remains difficult to distinguish the causes from the effects of aging, but studies abound that attempt to classify and explain the molecular and phenotypic changes that constitute aging.
There are many obstacles to researchers engaged in the pursuit of understanding human aging. The duration of such studies, limited longevity of researchers, and decades necessary for the human aging process to develop nearly prohibit these studies from being done in vivo. The need for adequate models from which we can extrapolate knowledge of human aging persists, but the choice of such models is far from straightforward.
The short life cycles of animals such as Drosophila melanogaster and Caenorhabditis elegans or the extensive work done on unicellular Saccharomyces cerevisiae make them attractive systems to gerontologists, but it is questionable whether these organisms provide the best possible representations of human aging processes. For example, although many of the genes that modulate aging have been found and studied in Drosophila and C. elegans, the fact that these animals are comprised of mainly postmitotic cells and do not get cancer raises questions about how well information garnered from them translates to human physiology. Moreover, the aging phenotypes displayed in yeast and humans are very dissimilar (80) .
The study of reptiles and other long-lived animals has been previously overlooked, but now promises to yield interesting findings. 'Anti-aging' pathways apparently unique to reptiles have been identified that could explain increased longevity in these species (82) . It is also important to note that some amphibians and fish exhibit "negligible senescence" (83-84) and long-lived birds have high metabolic rates and relatively slow rates of aging (85) (86) .
Species which are evolutionarily closer to humans arguably should provide data more representative of human aging processes than that from distant relatives. Short-lived mammals such as Mus musculus lend fewer clues to human aging because of findings that telomerasenegative mice are normal for multiple generations (87) and overexpression of telomerase in mice does not alter aging as it does in human systems (88) . Longer lived mammals that are more closely related to humans such as primates, elephants, and whales can better explain the evolution of longevity and be used to corroborate the data gathered from research on lower life forms.
Senescence
The ideal model system to study human aging is, of course, the humans. The aforementioned limitations of aging studies in vivo necessitated the development of in vitro aging systems. The study of cell culture to accurately model human biology led to the first formal description of senescence (89) . Senescence refers to the limited proliferative capacity of normal cells in vitro (reviewed in 90). It is important to make the distinction between terminology associated with senescence and, consequently, relationships to aging. The phrase 'replicative senescence' (RS) generally refers to the state of cells that have been cultured for extended periods of time in vitro which renders them incapable of further cell divisions. The causative event of replicative senescence in human cell lines appears to be telomere shortening (91) (92) . The role of telomere shortening as a putative 'molecular clock' that triggers replicative senescence after a species-dependent number of cell divisions has been extensively studied (93) (94) , but other data suggest that this particular type of senescence does not represent the most accurate model for human aging in vivo. Certain other mammals, such as mice and possibly other rodents, do not exhibit RS due to telomere shortening (96) . Moreover, immortal cell lines that are telomerase-negative have been reported (97) .
The more general concept of 'cellular senescence' may be more applicable with regards to modeling aging. Cellular senescence encompasses telomeric attrition and any other means by which cells are forced into the senescent state. Numerous studies have shown that events such as oxidative stress, ionizing radiation, and expression of some signal transduction molecules and cyclin-dependent kinase inhibitors can all lead to cellular senescence (98-100). Busuttil et al. (101) propose that the factors leading to genomic instability can also cause senescence and that this link may be associated with human aging. Other factors that can arguably induce senescence include discrete genetic components (102) and the loss of heterochromatin. Studies such as those outlined by Ogryzko et al. (103) reinforce the observation that multiple counting mechanisms act to limit the proliferative potential of cells. The addition of sodium butyrate or trichostatin A reversibly inhibit histone deacetylases and activate local transcription, yet cause an irreversible cell cycle exit. The presence of these epigenetic modulators during cell division must, therefore, alter the actions of additional proliferative control mechanism such as DNA methylation. As the loss of CpG methylation is also correlated with a senescent phenotype, it follows that these actions may act in concert in a pathway independent of telomeric length.
The well-characterized senescent phenotype of human diploid fibroblasts generally includes the gradual decrease in growth rate and eventual growth arrest in the G1-S transition (104) 
Aging
In contrast to senescence, the process of aging is a well-described, strictly in vivo phenomenon. Aging was described by Medawar in 1952 as the collection of changes that human beings undergo that progressively renders them more likely to die (117) and encompasses a broad variety of phenotypic changes. These changes can include, but are not limited to, decline in biological functions, decreased ability to maintain homeostasis, decline in cognitive functions (118) , reduced hypothalamic antioxidant defenses (119), increased obesity (especially an increase in visceral, relative to subcutaneous, fat deposition [120] ), loss of collagen elasticity, accumulation of potentially oxidized biological material in plaques (121) , increased insulin resistance, etc. It is often difficult to distinguish these changes from aging-related pathologies such as macular degeneration, atherosclerosis, presbyopia, diabetes, declination in immune function, renal diseases, and cancers.
Aging is known to be associated with universal molecular changes such as telomere shortening (122) and decreased DNA methylation that could potentially be used as counting mechanisms by cells. Slack et al. (123) found that SV40-mediated transformation of mouse Balb/c 3T3 cells is dependent on the increased DNA methyltransferase (MeTase) mRNA, protein levels, and MeTase-related global methylation induced by Large T antigen expression. In an examination of differential activity of maintenance and de novo DNA methyltransferases during cellular aging, Lopatina et al. (124) found a significant decrease in maintenance methylation corresponding to decreased Dnmt1 activity. As Dnmt1 is the major DNA methyltransferase in mammalian cells, these findings help to elucidate the mechanisms responsible for the age-related decline in cytosine methylation as cells age. The fact that manipulations of a relatively small number of genes and pathways can generate an aging phenotype suggests that the widespread effects of aging are controlled by discrete genetic components. Consequently, the geneticallyexplainable theories of aging center around energy metabolism and caloric restriction (125) , free radicals and DNA damage (126) (127) , and telomerase/senescence (93-94).
Senescence as an accurate model for aging
Many lines of evidence suggest that the study of telomere shortening and cellular senescence serves as an appropriate model for human aging. First, telomere shortening has been observed in vivo (128) (129) and the shortening has been correlated to decreased proliferative potential (130) (131) (132) . Second, senescent cells and senescence-biomarkers can be found in vivo and the senescence is associated with pathologies (135) . Third, cellular senescence has been described as a mechanism evolved to deter tumorigenesis (136) and there is considerable overlap between cell cycle checkpoint pathways and regulators of telomerase (refer to Section 2.3). Lastly, the study of epigenetic mechanisms that control senescence and the regulation of telomerase have great potential to yield clues in areas such as development, disease, and human aging. Minamino et al. (133) observed senescence-associated β-galactosidase staining in atherosclerotic lesions of subjects with ischemic heart disease. Moreover, this group found that inhibiting telomerase in human aortic endothelial cells (HAECs) was enough to induce senescence and that the introduction of telomerase prolonged the lifespan of these cells and inhibited the endothelial dysfunction associated with senescence. Cellular senescence was also found to be associated with the pathogenesis of benign prostatic hyperplasia. The accumulated senescent epithelial cells expressing Il-1α increased the proliferation of nearby nonsenescent cells, contributing to this common pathology observed in older men (134) . Shortened telomeres in certain mouse systems have even mimicked agingassociated phenomena such as graying hair, reduced stress response, and ulceration (159) . Epigenetic manipulations of human cells also alter telomerase expression and shorten their lifespan (refer to Section 2.2).
AGING AND TELOMERASE
Stem cells -a model for aging
Stem cells are generally defined as progenitor cells that are able to differentiate into multiple cell lineages, and are well-known for their self-renewal ability. Moreover, stem cells are able to repopulate the tissue of origin when transplanted into a damaged recipient (137) . The race to study the properties of stem cells and manipulate their development for transplantation therapy has also prompted scientists to turn to stem cells as a model for aging. Since stem cells are less or undifferentiated, they are ideal to study the related genetic response to environmental cues pertinent for cellular commitment into a specific differentiated phenotype, correlating with the onset of aging.
Since hTERT expression can be controlled epigenetically and by cell-cycle regulators including the tumor suppressor p53, the oncogene c-Myc, the tumor suppressor WT1 (in kidney, gonads, and spleen), and even estrogen (138) , this suggests that there is a tight regulation of hTERT and its expression is highly responsive to cellular environmental cues. Because of the natural phenomenon of telomeric attrition with each cell division in the absence of telomerase, it is therefore pertinent for highly replicative cells (like stem cells) to maintain the levels of telomerase for chromosomal stability, which immediately implicates hTERT. Changes in the lengths of telomeres, secondary to modulations in the levels of telomerase are therefore considered by some scientists as a biological clock for the aging process (139). This section discusses the expression of telomerase in embryonic, adult, and abnormal stem cells, and the use of these cells as tools for aging research.
hTERT and telomerase in embryonic stem cells
Embryonic stem (ES) cells are pluripotent cells that are surgically extracted from an embryo at the blastocyst stage. The cells are derived from the inner cell mass (ICM), the part of the blastocyst that will eventually give rise to all tissue lineages and even some extraembryonic tissues. In association with their ability to remain in the undifferentiated state and their highly proliferative nature (140), human ES (hES) cells express a high level of telomerase activity that is 3.8 to 5.9 times greater than that expressed by MDA, an immortal human breast carcinoma cell line (141) .
Embryoid bodies (EB) are formed from ES cells by allowing the aggregation of ES cells cultured in suspension or in methyl cellulose-containing medium. EB formation is characterized by the spontaneous differentiation of the aggregated ES cells, and is a requisite for the development of ES pluripotent cell lineage potential. EB formation therefore provides a powerful tool to study early lineage formation during mammalian development. It has been determined from the expression of developmental markers that the differentiation stages in EB formation are congruent with the stages of the developing embryo such as implantation to early gastrulation, gastrulation, and early organogenesis (142) . EB can be further cultured by surgically grafting them into immuno-compromised mice, resulting in the formation of EB-derived teratomas, which could become malignant (143) . EB are not transformed cells, and consistent with this fact, they are found to be telomerase-negative, suggesting a reason why embryoid-derived cell cultures are capable of only about 40 population doublings in vitro before the onset of senescence (144) due to telomeric attrition. Recent studies have found that a global demethylation occurs as ES cells transition into EB (145) , which supports the findings of Shamblott et al., 2001 who determined that embryoid-derived cultures were telomerase-negative due to hypomethylation of the hTERT promoter which causes reduced hTERT expression and telomerase activity (146) . Therefore it appears likely that epigenetic processes such as DNA methylation are involved in the transition of ES cells into EB.
hTERT and telomerase in adult stem cells
Adult stem cells are multipotent, meaning that they are able to differentiate into a restricted number of lineages. There are, however, certain stem cells that give rise to only one type of mature cell type, for example, the corneal stem cell. Adult stem cells can be found in almost every organ in the body except possibly the heart, and are usually in a minority population of 1-2% or less of total cellularity. These adult stem cells exist for the purpose of tissue regeneration or cell renewal, especially during stress or insult (reviewed in 147). The study of adult stem cells may be important to understand how cellular and whole tissue regeneration occurs or fails to do so in vivo, as the human body undergoes the aging process.
Although most adult stem cells express low to moderate levels of telomerase, it is surprising that human mesenchymal stem cells (hMSCs) are found to be telomerase-negative. This indicates that they have a replication limit, which was demonstrated when hMSCs were cultured in vitro until they reached their lifespan replication limit of about 18.7 population doublings (148) . Transducing hMSCs with hTERT causes the hMSCs to exhibit characteristics of transformed cells, such as loss of contact inhibition, anchorage independence, and tumor formation in mice (149).
hTERT and telomerase in abnormal stem cells
Germ cell tumors, such as male germ cell tumors (seminomas), consist of abnormal stem cells formed from germ cell progenitors that are able to undergo extensive differentiation to form teratomas (150) . Undifferentiated embryonic carcinomas, which are also termed immature teratomas, can give rise to mature teratomas that are either benign or malignant. These abnormal embryonic stem cells, like normal embryonic stem cells, are pluripotent and differentiate into a disorganized array of every type of cell lineages, such that it is not uncommon for teratomas to come complete with hair and teeth. Normal germ cell progenitors and undifferentiated embryonic carcinomas have high levels of telomerase activity. It has been demonstrated that mature teratomas do not express a detectable level of telomerase which could explain why they have limited proliferative capacity (151) even though some mature teratomas possess long telomeres (152) . Abnormal stem cells provide a means to study the differentiation state of tumor cells and its relationship to telomerase expression. Also, since there is an overlap of genetic expression between these cells and normal embryonic stem cells, it makes practical sense to study these abnormal stem cells as they are simpler to culture.
Human embryonic teratocarcinoma (HT) cells are transformed stem cells that are totipotent and express high levels of telomerase. The hTERT promoter is unmethylated, allowing for telomerase to be highly transcribed in these particular cells (153) . When undifferentiated HT cells were treated with retinoic acid to induce differentiation, a progressive methylation of the hTERT promoter coupled with a down-regulation of hTERT was observed. Methylation has been shown to be more pronounced in the distal E-box than the proximal E-box of the hTERT promoter, suggesting a control mechanism via epigenetic modification during differentiation to prevent c-Myc/Max protein complex from binding at the promoter. Interestingly, silencing of the hTERT promoter after initial differentiation due to histone deacetylation was followed by methylation at later stages of differentiation, indicating that methylation change is a mechanism used for stable inactivation of hTERT (153).
Werner syndrome: a premature aging disease associated with telomerase
Werner syndrome (WS) is an autosomal recessive disorder in which patients show symptoms of premature aging such as graying of hair, cataracts, diabetes mellitus, osteoporosis, and atherosclerosis, and they also display a high incidence of malignant tumors, specifically sarcomas. The average lifespan of a patient with WS is 47 years of age (154) (155) . WS is caused by a mutation in the gene which encodes for a RecQ helicase protein, WRN (156) . This helicase also displays a 3' to 5' exonuclease activity, and both functions may work in coordination to remove DNA repair and recombination intermediates. WRN helicase and exonuclease function to resolve the 3' protective intratelomeric D loop structure, releasing the T loop to allow for telomere replication (157) . Telomere binding proteins, TRF1 and TRF2 bind to and protect the telomeres from nuclease digestion, thus allowing for regulation of WRN exonuclease activity. Data has shown that WRN colocalizes with ALT-associated PML bodies (APB; see section on alternate lengthening of telomeres) during S phase in ALT cells (157) , suggesting that WRN is involved in a mechanism preventing homologous recombination of telomeres in normal cells.
It has been demonstrated that WRN null fibroblasts undergo a higher telomere attrition rate, causing premature senescence in the cells. The fact that this accelerated rate of senescence can be rescued by hTERT expression supports the theory that telomere attrition is the key problem in WS (158) . Further, knocking out hTR in mice causes an acceleration of the already early onset of premature aging symptoms paralleled in WS (159) . Recent evidence has shown that WS cell senescence is p53-dependent and based on telomere-induced lifespan barriers, since p53 and p21 WAF1 expression is up-regulated in WS fibroblast cells (160) . In addition, it is interesting to note that the p53 / p21 WAF1 pathway also suppresses hTERT transcription (see section 2.3), lending to increased telomeric attrition. It could be hypothesized that the lack of telomerase activity in WS cells could promote ALT occurrence, and WRN deficiency cannot resolve homologous recombination in telomeres causing telomeric DNA strand breaks.
The loss of WRN function in WS results in genomic instability due to problems with DNA repair and replication, defects in homologous recombination, chromosomal alterations, problems with telomere maintenance, and a high rate of apoptosis (reviewed in 155).
Telomerase activity in cancer and other agingrelated diseases
As a general rule, mature mammalian systems require significant capacities for tissue repair and, occasionally, regeneration to combat rates of cellular attrition. In light of the extensive tissue proliferation that occurs even under nonpathological conditions, there must be inherent tumor suppressor mechanisms that regulate the growth of potential cancer cells. Indeed, the three principle tumor suppressor pathways, namely proteins encoded by the INK4a/ARF locus, p53, and telomeric attrition all overlap and play important roles in the cellular processes of senescence, tumorigenesis, and aging. Since telomere activity has been shown to correlate with stages of tumorigenesis and metastasis (reviewed in 161), early reactivation of telomerase activity can potentially be used as a prognostic marker for early detection of certain cancers such as primary lung, breast, colorectal, bladder, renal, thyroid, and pancreatic cancers (162) (163) (164) (165) (166) (167) . The prevalence of telomerase reactivation seen in malignancies points to telomerase inhibition as a therapeutic strategy. Indeed, inhibiting telomerase in cancer cells by such mechanisms as introduction of dominant negative hTERT vectors, antisense hTERT, and immune recognition has resulted in marked decreases in cell proliferation and viability (168) (169) (170) .
The regulation of telomerase by transcriptional and epigenetic mechanisms (reviewed in 171) has important implications in the onset of cancer. The integration of genetic and epigenetic information provides the necessary framework to resolve the links between telomerase, aging, and cancer. It is interesting to note that epigenetic changes are more widely associated with tumorigenesis than specific genetic mutations (172) . Moreover, the global hypomethylation that occurs during aging may be the mechanism by which the epigenetic programming is disrupted and risk of cancer is increased. The late onset of common disorders that involve complex genetics can only be examined in light of epigenetic variations, considering the fact that the genome and hence genetic factors are present since birth. Bjornsson et al. propose that epigenetic marks add another layer of complexity that could contribute to the variability in disease phenotypes, namely age of onset, response to treatment and environmental stimuli, difference in severity, and rate of progression (173) . Thus, it is imperative to study the relationship between the genetic and epigenetic modifications that control telomerase activity. Recent studies even suggest that the down-regulation of hTERT by transcriptional repressors precedes epigenetic modifications that stabilize and maintain the silenced state (174) (175) .
In addition to cancer and senescence-associated tissue malfunctions, telomere dysfunction has also been linked to a number of aging-related pathologies. The syndrome known as dyskeratosis congenita involves skin and bone marrow failure reminiscent of accelerated aging. Mutations in the protein encoded by DKC1, dyskerin, lead to this disorder characterized by cancer predisposition and more severe manifestations in later generations, suggesting the involvement of telomere shortening. DCK1 is actually a component of the telomerase holoenzyme (reviewed in 176). A second progeroid syndrome, ataxia telangiectasia, is caused by a deficiency of the AT tumor suppressor (ATM, ataxia telangiectasia mutated kinase). ATM is known to be involved in p53 activation induced by DNA damage and the resulting premature telomere shortening produces patients prone to tumor formation, immunodeficiency, neurodegeneration and skin and hair changes (177) . Similarly, Fanconi anemia is characterized by bone marrow failure and the propensity to develop acute myeloid leukemias (178) . Accelerated telomere attrition is linked to the progression of this disease (179) . The severity of atherosclerosis also inversely correlates with telomere length (180) . The extensive telomere shortening in the vascular system driven by the need to combat cell loss could actually contribute to atherosclerotic plaque formation (181) . Aberrant telomere shortening has also been linked to the development of cirrhosis in the livers of hepatitis patients and even Alzheimer's disease (182) (183) . Although the restoration of physiological levels of telomerase activity appears an attractive strategy for treating these disorders, care must be taken to prevent oncogenic transformation.
CONCLUSION
Epigenetic modulations work in sync with genetic elements to ensure proper cooperation of the tightly-linked telomerase activity and cell proliferation regulatory pathways. Aging studies have concentrated efforts on the activation of telomerase to prevent or delay aging and prolong disease-free survival. Expansion of telomerase-immortalized cells for in vitro tissue engineering and reimplantation is a cell-based therapy for aging related diseases that involve the loss of irreplaceable cells. It is unknown whether manipulations of telomere length by processes which activate telomerase would be useful for clinical therapy. Furthermore, the risks of side effects or secondary changes like oncogenic transformation in cells ectopically expressing telomerase must be taken under consideration and studied in appropriate model systems. With increases in knowledge of telomere biology, it might be possible to treat aging-associated ailments before we fully understand the particulars of how telomerase contributes to factors resulting in human aging. Information on the involvement of telomerase in cancer appears to be advancing at a faster rate than knowledge of the association between telomerase and aging. The field of epigenetics is poised to answer many of the long-standing questions regarding hTERT regulation, aging, and cancer. Moreover, epigenetic approaches integrated with information from genetic studies can further explain the effects of common complex diseases and variations of their aging-related phenotypes. 
